http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer
-
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
-
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update
-
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026
-
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
-
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
-
FDA accepts Exelixis drug application for colorectal cancer treatment
-
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
-
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
-
Exelixis reports $2.123 billion preliminary 2025 revenues, guides higher for 2026
-
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
-
Exelixis and Natera partner on phase 3 colorectal cancer trial
-
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
-
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
-
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
-
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November
-
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update
-
Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025
-
Exelixis reports survival benefit for zanzalintinib combo in colorectal cancer
-
Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO
-
EXEL reports CABOMETYX reduced disease progression risk by 81% in lung tumors
-
Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025
-
Exelixis names Dana Aftab as executive vice president of R&D
-
Exelixis Announces Appointment of Dana T. Aftab, Ph.D. as Executive Vice President, Research and Development
-
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
-
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update
-
Exelixis partner Ipsen gets EU approval for neuroendocrine tumor treatment
-
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
-
Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025
-
Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer
-
Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
-
Exelixis (EXEL) announces results from Phase1b/2 trial evaluating Zanzalintinib
-
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025
-
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June
-
Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update
-
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
-
Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025
-
Exelixis (EXEL) Announces U.S. FDA Approval of CABOMETYX
-
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
-
Exelixis to Present Positive Preclinical Data Across Its Pipeline Portfolio for Advanced Cancers at AACR 2025
-
Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
-
Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
-
Exelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at
-
Exelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
-
Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
-
Exelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
-
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI
-
Exelixis (EXEL) Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study
-
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
-
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
